Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Income from Continuing Operations (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Income from Continuing Operations for 11 consecutive years, with 90397000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations changed N/A to 90397000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 139137736.0 through Dec 2025, changed N/A year-over-year, with the annual reading at 153942000.0 for FY2025, 293.67% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 90397000.0 at Crescent Biopharma, down from 24607000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 2343736.0 in Q1 2025, with the low at 90397000.0 in Q4 2025.
  • Average Income from Continuing Operations over 5 years is 16295603.58, with a median of 10736667.0 recorded in 2024.
  • Peak annual rise in Income from Continuing Operations hit 78.17% in 2025, while the deepest fall reached 835.27% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 17421796.0 in 2021, then soared by 41.2% to 10244355.0 in 2022, then increased by 11.38% to 9078640.0 in 2023, then surged by 71.02% to 2631000.0 in 2024, then crashed by 3335.84% to 90397000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 90397000.0, 24607000.0, and 21790000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.